Google Inc vs Mesoblast Limited — how do they compare? Google Inc trades at $347.86 (market cap $4.24T), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Google Inc is far larger — about 2422.9× Mesoblast Limited's market cap, and Google Inc pays a 0.26% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Google Inc for 137 Days and Mesoblast Limited for 15 Days on average.
| GOOG | MESO | |
|---|---|---|
Market Cap | $4.24T | $1.75B |
Volume | 13,937,902 | 239,027 |
Sector | Media | Health |
52-Week High | $399.06 | $20.96 |
52-Week Low | $237.49 | $13.19 |
Typical Hold Time | 137 Days | 15 Days |
Enterprise Value | $4.13T | $1.83B |
Dividend Yield | 0.26% | — |
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $344.86, down 0.72% on the day, with strong technical support at $342 and resistance at $348. The company demonstrates robust fundamentals with 2025 revenue of $402.84B and net income of $132.17B, achieving consistent earnings beats in recent quarters. Analyst sentiment remains overwhelmingly positive with 87% buy ratings and a $435.24 consensus price target, representing 26% upside potential.
The outlook remains favorable given Alphabet's dominant market position and AI leadership, though investors should monitor elevated capital expenditures and potential regulatory risks. The stock's current valuation at 17.3x P/E appears reasonable relative to growth prospects, with upcoming Q3 earnings on October 31, 2026, serving as the next key catalyst.
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →